3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
4
Multiple Myeloma
3
Glioma
3
Thyroid Neoplasms
2
Lymphoma
2
Hematologic Neoplasms
2
Glioblastoma
2
Astrocytoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurocytoma
1
Neuroblastoma
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Ganglioneuroma
1
Ganglioglioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Interventions
Gemcitabine
8
Cisplatin
8
durvalumab
4
Oxaliplatin
3
Irinotecan
3
Folfox protocol
3
Bevacizumab
3
zanidatamab
2
pembrolizumab
2
Fluorouracil
2
Capecitabine
2
tremelimumab
1
trastuzumab deruxtecan
1
toripalimab
1
poly ICLC
1
niraparib
1
neratinib
1
ivosidenib
1
futibatinib
1
fludarabine
1
envafolimab
1
encorafenib
1
brigimadlin
1
binimetinib
1
apatinib
1
Trastuzumab
1
Self Expandable Metallic Stents
1
Psilocybin
1
Peptides
1
Pemetrexed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
dabrafenib
×
30 days
×
Clear all
No trials found.